DK3733712T3 - Programmer og fremgangsmåder til behandling af multipel sklerose under anvendelse af ofatumumab - Google Patents
Programmer og fremgangsmåder til behandling af multipel sklerose under anvendelse af ofatumumab Download PDFInfo
- Publication number
- DK3733712T3 DK3733712T3 DK20180938.1T DK20180938T DK3733712T3 DK 3733712 T3 DK3733712 T3 DK 3733712T3 DK 20180938 T DK20180938 T DK 20180938T DK 3733712 T3 DK3733712 T3 DK 3733712T3
- Authority
- DK
- Denmark
- Prior art keywords
- ofatumumab
- programs
- treatment
- methods
- multiple sclerosis
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title 1
- 229960002450 ofatumumab Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Pressure Welding/Diffusion-Bonding (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374986P | 2016-08-15 | 2016-08-15 | |
| EP17768863.7A EP3497132B1 (en) | 2016-08-15 | 2017-08-11 | Regimens and methods of treating multiple sclerosis using ofatumumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3733712T3 true DK3733712T3 (da) | 2023-08-21 |
Family
ID=59901554
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17768863.7T DK3497132T3 (da) | 2016-08-15 | 2017-08-11 | Regimer og fremgangsmåder til behandling af multipel sclerose under anvendelse af ofatumumab |
| DK20180938.1T DK3733712T3 (da) | 2016-08-15 | 2017-08-11 | Programmer og fremgangsmåder til behandling af multipel sklerose under anvendelse af ofatumumab |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17768863.7T DK3497132T3 (da) | 2016-08-15 | 2017-08-11 | Regimer og fremgangsmåder til behandling af multipel sclerose under anvendelse af ofatumumab |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11161909B2 (da) |
| EP (4) | EP3497132B1 (da) |
| JP (2) | JP6851391B2 (da) |
| KR (2) | KR20190038914A (da) |
| CN (1) | CN109641965A (da) |
| AU (2) | AU2017311664B2 (da) |
| CA (2) | CA3030530C (da) |
| CY (1) | CY1123350T1 (da) |
| DE (1) | DE202017007542U1 (da) |
| DK (2) | DK3497132T3 (da) |
| ES (2) | ES2821924T3 (da) |
| FI (1) | FI3733712T3 (da) |
| HR (2) | HRP20230894T1 (da) |
| HU (2) | HUE051948T2 (da) |
| IL (3) | IL302488A (da) |
| LT (2) | LT3733712T (da) |
| MX (1) | MX2019001860A (da) |
| PL (2) | PL3733712T3 (da) |
| PT (2) | PT3733712T (da) |
| RS (2) | RS64541B1 (da) |
| RU (1) | RU2749951C2 (da) |
| SI (2) | SI3733712T1 (da) |
| TW (1) | TWI752995B (da) |
| WO (1) | WO2018033841A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3733712T3 (pl) * | 2016-08-15 | 2023-10-16 | Novartis Ag | Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu |
| EP3864053B1 (en) | 2019-09-11 | 2023-07-05 | Novartis AG | Treatment of rms by switching therapy |
| MX2022003030A (es) | 2019-09-11 | 2022-04-07 | Novartis Ag | Tratamiento de afecciones distintas de la esclerosis multiple en pacientes tratados con ofatumumab. |
| CN117529336A (zh) * | 2021-04-14 | 2024-02-06 | 诺华股份有限公司 | 用于治疗亚洲患者的多发性硬化症的奥法木单抗 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| JP2014506258A (ja) * | 2011-01-10 | 2014-03-13 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 新規使用 |
| MX363819B (es) * | 2012-02-08 | 2019-04-03 | Igm Biosciences Inc | Uniones a cdim y sus usos. |
| GEP201706748B (en) | 2012-08-10 | 2017-10-10 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| WO2016123329A2 (en) * | 2015-01-28 | 2016-08-04 | Genentech, Inc. | Gene expression markers and treatment of multiple sclerosis |
| PL3733712T3 (pl) * | 2016-08-15 | 2023-10-16 | Novartis Ag | Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu |
-
2017
- 2017-08-11 PL PL20180938.1T patent/PL3733712T3/pl unknown
- 2017-08-11 SI SI201731396T patent/SI3733712T1/sl unknown
- 2017-08-11 CA CA3030530A patent/CA3030530C/en active Active
- 2017-08-11 DE DE202017007542.3U patent/DE202017007542U1/de active Active
- 2017-08-11 LT LTEP20180938.1T patent/LT3733712T/lt unknown
- 2017-08-11 US US16/324,619 patent/US11161909B2/en active Active
- 2017-08-11 ES ES17768863T patent/ES2821924T3/es active Active
- 2017-08-11 IL IL302488A patent/IL302488A/en unknown
- 2017-08-11 EP EP17768863.7A patent/EP3497132B1/en active Active
- 2017-08-11 DK DK17768863.7T patent/DK3497132T3/da active
- 2017-08-11 LT LTEP17768863.7T patent/LT3497132T/lt unknown
- 2017-08-11 ES ES20180938T patent/ES2954259T3/es active Active
- 2017-08-11 MX MX2019001860A patent/MX2019001860A/es unknown
- 2017-08-11 HU HUE17768863A patent/HUE051948T2/hu unknown
- 2017-08-11 KR KR1020197007454A patent/KR20190038914A/ko not_active Application Discontinuation
- 2017-08-11 AU AU2017311664A patent/AU2017311664B2/en active Active
- 2017-08-11 PT PT201809381T patent/PT3733712T/pt unknown
- 2017-08-11 PL PL17768863T patent/PL3497132T3/pl unknown
- 2017-08-11 CA CA3101514A patent/CA3101514A1/en active Pending
- 2017-08-11 SI SI201730400T patent/SI3497132T1/sl unknown
- 2017-08-11 EP EP20180938.1A patent/EP3733712B1/en active Active
- 2017-08-11 IL IL276890A patent/IL276890B2/en unknown
- 2017-08-11 HR HRP20230894TT patent/HRP20230894T1/hr unknown
- 2017-08-11 CN CN201780049932.7A patent/CN109641965A/zh active Pending
- 2017-08-11 RS RS20230635A patent/RS64541B1/sr unknown
- 2017-08-11 KR KR1020207034140A patent/KR20200136503A/ko not_active IP Right Cessation
- 2017-08-11 HU HUE20180938A patent/HUE063625T2/hu unknown
- 2017-08-11 RU RU2019107146A patent/RU2749951C2/ru active
- 2017-08-11 JP JP2018550539A patent/JP6851391B2/ja active Active
- 2017-08-11 EP EP23172507.8A patent/EP4252847A3/en active Pending
- 2017-08-11 RS RS20201066A patent/RS60807B1/sr unknown
- 2017-08-11 DK DK20180938.1T patent/DK3733712T3/da active
- 2017-08-11 EP EP24166956.3A patent/EP4371611A2/en active Pending
- 2017-08-11 FI FIEP20180938.1T patent/FI3733712T3/fi active
- 2017-08-11 PT PT177688637T patent/PT3497132T/pt unknown
- 2017-08-11 WO PCT/IB2017/054909 patent/WO2018033841A1/en unknown
- 2017-08-15 TW TW106127565A patent/TWI752995B/zh active
-
2019
- 2019-02-12 IL IL264804A patent/IL264804B/en active IP Right Grant
-
2020
- 2020-02-07 JP JP2020019337A patent/JP7198786B2/ja active Active
- 2020-02-17 AU AU2020201112A patent/AU2020201112B2/en active Active
- 2020-08-31 HR HRP20201388TT patent/HRP20201388T1/hr unknown
- 2020-09-11 CY CY20201100861T patent/CY1123350T1/el unknown
-
2021
- 2021-10-06 US US17/495,559 patent/US20220081488A1/en not_active Abandoned
-
2023
- 2023-06-08 US US18/331,701 patent/US20240150485A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255690A (en) | Method and application environment for safe execution of program instructions | |
| DK3259597T3 (da) | Pvrig-polypeptider og fremgangsmåder til behandling | |
| DK3173092T3 (da) | Rna-holdig sammensætning til behandling af tumorsygdomme | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
| DK3402888T3 (da) | Middel og fremgangsmåder til behandling af hbv | |
| DK3096798T3 (da) | Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem | |
| DK3350201T3 (da) | Manipulerede fytaser og fremgangsmåder til anvendelse af samme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
| DK3183010T3 (da) | Anordning og tilhørende fremgangsmåde til behandling af medicinsk affald | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
| DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
| DK3334693T3 (da) | Kontinuerlig fremgangsmåde og system til behandlingen af spildevand | |
| DK3157522T3 (da) | Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste | |
| DK3733712T3 (da) | Programmer og fremgangsmåder til behandling af multipel sklerose under anvendelse af ofatumumab | |
| DK3286317T3 (da) | Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi | |
| DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi | |
| DK3122743T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme | |
| DK3229827T3 (da) | Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme | |
| DK3313042T3 (da) | Fremgangsmåder og apparater til betinget wifi-roaming | |
| KR20180084928A (ko) | 특히 전류의 도움으로 인간 케라틴 물질을 처리하기 위한 디바이스 |